Form 4: Minerva Neurosciences Director Granted Stock Options

Minerva Neurosciences director David Kupfer was granted 50,000 stock options with an exercise price of $3.98, vesting quarterly over one year.

Summary

• David Kupfer, a director at Minerva Neurosciences, Inc. (NERV), was granted 50,000 stock options.
• The transaction date for this grant is December 22, 2025.
• The exercise price for these options is $3.98 per share.
• The options vest in four equal quarterly installments, with 1/4 of the total shares vesting every three months.
• The first vesting date is three months following December 22, 2025, and an additional 1/4 vesting every three months thereafter.
• Vesting is contingent upon Mr. Kupfer's continued service as a non-employee director as of each vesting date.
• The options have an expiration date of December 21, 2035.
• Following this transaction, Mr. Kupfer beneficially owns 50,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive. This is a routine insider transaction that aligns director incentives with shareholder interests, indicating continued commitment from a key board member. No significant new financial or operational information is disclosed that would drastically alter sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedule encourages continued service and commitment from the director to the company's strategic objectives.

Negatives

• No direct negatives are presented in this routine insider transaction filing.

Risks

• The value of the stock options is dependent on the future market price of Minerva Neurosciences, Inc. common stock, and they will only have intrinsic value if the stock price exceeds the exercise price of $3.98.
• Vesting is subject to the director's continued service, meaning unvested options could be forfeited if service ceases before the vesting dates.

Future Outlook

The grant of stock options with a vesting schedule extending over one year and an expiration date ten years out indicates an expectation of continued long-term service from David Kupfer as a director and aligns his future financial interests with the company's stock performance.

Industry Context

Granting stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, as well as other sectors, to attract and retain qualified board members and align their incentives with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of non-employee director compensation across many industries, including biotech.
• The size of the grant (50,000 options) and the exercise price ($3.98) would typically be evaluated against peer companies of similar market capitalization and stage of development to determine if it is competitive and appropriate within the industry.

Corporate Governance

Related Party Transactions

• The grant of 50,000 stock options to David Kupfer, a non-employee director, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused governance and strategic decisions aimed at increasing stock price.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The stock options will begin vesting in four equal quarterly installments, with the first vesting three months after December 22, 2025.
• David Kupfer's continued service as a non-employee director is required for the options to vest.

Key Dates

Keywords

Minerva Neurosciences, NERV, David Kupfer, Stock Options, Insider Transaction, Director Compensation, SEC Form 4, Equity Grant, Vesting